Samsara BioCapital’s Day One Biopharmaceuticals DAWN Stock Holding History

Samsara BioCapital’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-147,319	Closed	-$1.87M	–	39
2024 Q4	$1.87M	Hold	147,319	–	–	0.26%	30
2024 Q3	$2.05M	Sell	147,319 -49,106	-25%	-$701K	0.39%	29
2024 Q2	$2.71M	Hold	196,425	–	–	0.57%	27
2024 Q1	$3.24M	Hold	196,425	–	–	0.5%	28
2023 Q4	$2.87M	Hold	196,425	–	–	0.45%	27
2023 Q3	$2.41M	Hold	196,425	–	–	0.74%	28
2023 Q2	$2.35M	Hold	196,425	–	–	0.41%	28
2023 Q1	$2.63M	Hold	196,425	–	–	0.54%	28
2022 Q4	$4.23M	Hold	196,425	–	–	0.91%	25
2022 Q3	$3.93M	Hold	196,425	–	–	0.92%	24
2022 Q2	$3.52M	Sell	196,425 -6,075	-3%	-$62.7K	0.94%	25
2022 Q1	$2.01M	Hold	202,500	–	–	0.51%	39
2021 Q4	$3.41M	Hold	202,500	–	–	0.66%	30
2021 Q3	$4.8M	Hold	202,500	–	–	0.75%	30
2021 Q2	$4.61M	Buy	+202,500	New	+$4.22M	0.57%	29

Other funds holding DAWN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ECM

Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return

Samsara BioCapital's DAWN Position: Q1 2025 in Review

Samsara BioCapital sold out of Day One Biopharmaceuticals (DAWN) in Q1 2025, closing a stake of 147,319 shares — an estimated $1.87M sold.

Samsara BioCapital first reported a position in DAWN in Q2 2021 and held it in 15 quarters. The position peaked at $4.8M in Q3 2021. 184 funds tracked by Wall St. Rank hold DAWN as of Q1 2025.

Samsara BioCapital reported no remaining Day One Biopharmaceuticals position as of Q1 2025 after selling out during the quarter.
Samsara BioCapital sold 147,319 Day One Biopharmaceuticals shares in Q1 2025, an estimated $1.87M.
Samsara BioCapital first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 15 quarters.
Samsara BioCapital's Day One Biopharmaceuticals position peaked at $4.8M in Q3 2021.
184 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2025.

Based on Samsara BioCapital's 13F filing for Q1 2025, filed 15 May 2025.